Preclinical News and Research

RSS

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

AM-Pharma announces €29.2m series D round of financing

AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing.

13 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

Hawthorn, CoPlex Therapeutics sign licensing deal to develop and commercialize hawAD14 for Alzheimer's

Hawthorn Pharmaceuticals, Inc. announced today an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.

13 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

InnoCentive, JDRF announce $100,000 Challenge to uncover solutions for insulin-dependent diabetes

The Juvenile Diabetes Research Foundation (JDRF), the worldwide leader for research to cure, treat, and prevent type 1 diabetes, and InnoCentive, Inc., the pioneer in open innovation and crowdsourcing, today announced a $100,000 Challenge calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat insulin-dependent diabetes.

9 Sep 2011

Aura's NanoSmart platform can enable earlier detection, treatment of cancers

Aura Biosciences, Inc., a biotech company focused on the development of nano-enabled drug delivery systems, has completed several pre-clinical research programs. The resulting data suggest that Aura's NanoSmart platform can enable earlier detection of cancers and distant metastases; and then provide precisely targeted treatment of those cancers.

9 Sep 2011

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria

Positive results from the initial Phase 1 clinical trial in 80 healthy volunteers and complementary pre-clinical studies of the Sanaria PfSPZ Vaccine are published today in the online issue of Science.

9 Sep 2011

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

9 Sep 2011

'Chaperone' protein may play a critical role in pathogenesis of heart failure

Researchers at Mount Sinai School of Medicine have identified a new drug target that may treat and/or prevent heart failure. The team evaluated failing human and pig hearts and discovered that SUMO1, a so-called "chaperone" protein that regulates the activity of key transporter genes, was decreased in failing hearts.

8 Sep 2011

Researchers identify new drug target for heart failure

8 Sep 2011

ATA announces five recipients of 2011 thyroid cancer research grants

The American Thyroid Association (ATA) announced the five recipients of its 2011 research grants, each of whom will receive up to $25,000 annually for up to two years. Three of the five recipients were awarded special ATA ThyCa grants for research projects that focus on thyroid cancer. These grants are funded by ThyCa: Thyroid Cancer Survivors, Inc.

8 Sep 2011

Developing technologies to improve treatment of craniosynostosis in babies

Engineers and surgeons are working together to improve the treatment of babies born with craniosynostosis, a condition that causes the bone plates in the skull to fuse too soon. Treating this condition typically requires surgery after birth to remove portions of the fused skull bones, and in some cases the bones grow together again too quickly -- requiring additional surgeries.

8 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

Loss of estrogen receptor alpha protein may lead to metabolic syndrome

UCLA researchers demonstrated that loss of a key protein that regulates estrogen and immune activity in the body could lead to aspects of metabolic syndrome, a combination of conditions that can cause Type 2 diabetes, atherosclerosis and cancer. Called estrogen receptor alpha, this protein is critical in regulating immune system activity such as helping cells suppress inflammation and gobble-up debris.

7 Sep 2011

Preclinical News and Research

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

AM-Pharma announces €29.2m series D round of financing

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

Hawthorn, CoPlex Therapeutics sign licensing deal to develop and commercialize hawAD14 for Alzheimer's

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

New treatment strategy for dominant forms of muscular dystrophy

InnoCentive, JDRF announce $100,000 Challenge to uncover solutions for insulin-dependent diabetes

Aura's NanoSmart platform can enable earlier detection, treatment of cancers

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Positive results from Sanaria PfSPZ Vaccine initial Phase 1 trial on malaria

Bristol-Myers Squibb acquires Amira Pharmaceuticals

'Chaperone' protein may play a critical role in pathogenesis of heart failure

Researchers identify new drug target for heart failure

ATA announces five recipients of 2011 thyroid cancer research grants

Developing technologies to improve treatment of craniosynostosis in babies

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Loss of estrogen receptor alpha protein may lead to metabolic syndrome

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics